Edgar Filing: CONCERT PHARMACEUTICALS, INC.

Ownership Submission

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

TVM Life Science Ventures VI GmbH & Co KG

2. Issuer Name and Ticker or Trading Symbol
CONCERT PHARMACEUTICALS, INC. [CNCE]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	__X__ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

(Last)

(First)

(Middle)

C/O TVM CAPITAL GROUP, OTTOSTRASSE 4

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2014

(Street)

MUNICH, 2M 80333

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/19/2014		C		289,991	A	⁽¹⁾	329,535 ⁽²⁾	D ⁽²⁾
Common Stock	02/19/2014		C		560,211	A	⁽¹⁾	889,746 ⁽²⁾	D ⁽²⁾
Common Stock	02/19/2014		C		148,936	A	⁽¹⁾	1,038,682 ⁽²⁾	D ⁽²⁾
Common Stock	02/19/2014		C		99,389	A	⁽¹⁾	112,942 ⁽³⁾	I	By TVM Life Sciences Ventures VI LP ⁽³⁾
Common Stock	02/19/2014		C		192,003	A	⁽¹⁾	304,945 ⁽³⁾	I	By TVM Life Sciences Ventures VI LP ⁽³⁾
Common Stock	02/19/2014		C		51,045	A	⁽¹⁾	355,990 ⁽³⁾	I	By TVM Life Sciences Ventures VI LP ⁽³⁾
Common Stock	02/19/2014		P		66,287	A	$ 14	1,104,969 ⁽²⁾	D ⁽²⁾
Common Stock	02/19/2014		P		22,713	A	$ 14	378,703 ⁽³⁾	I	By TVM Life Sciences Ventures VI LP ⁽³⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Series A Convertible Preferred Stock

⁽¹⁾

02/19/2014

1,638,450

⁽¹⁾

⁽⁴⁾

Common Stock

289,991

$ 0

D ⁽²⁾

Series B Convertible Preferred Stock

⁽¹⁾

02/19/2014

3,165,187

⁽¹⁾

⁽⁴⁾

Common Stock

560,211

$ 0

D ⁽²⁾

Series C Convertible Preferred Stock

⁽¹⁾

02/19/2014

841,493

⁽¹⁾

⁽⁴⁾

Common Stock

148,936

$ 0

D ⁽²⁾

Series A Convertible Preferred Stock

⁽¹⁾

02/19/2014

561,550

⁽¹⁾

⁽⁴⁾

Common Stock

99,389

$ 0

By TVM Life Sciences Ventures VI LP ⁽³⁾

Series B Convertible Preferred Stock

⁽¹⁾

02/19/2014

1,084,813

⁽¹⁾

⁽⁴⁾

Common Stock

192,003

$ 0

By TVM Life Sciences Ventures VI LP ⁽³⁾

Series C Convertible Preferred Stock

⁽¹⁾

02/19/2014

288,407

⁽¹⁾

⁽⁴⁾

Common Stock

51,045

$ 0

By TVM Life Sciences Ventures VI LP ⁽³⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
TVM Life Science Ventures VI GmbH & Co KG C/O TVM CAPITAL GROUP OTTOSTRASSE 4 MUNICH, 2M 80333	X	X
Birner Hubert C/O TVM CAPITAL GROUP OTTOSTRASSE 4 MUNICH, 2M 80333		X
Fischer Stefan C/O TVM CAPITAL GROUP OTTOSTRASSE 4 MUNICH, 2M 80333		X
Goll Alexandra C/O TVM CAPITAL GROUP OTTOSTRASSE 4 MUNICH, 2M 80333		X
Polack Axel C/O TVM CAPITAL GROUP OTTOSTRASSE 4 MUNICH, 2M 80333		X
SCHUHSLER HELMUT C/O TVM CAPITAL GROUP OTTOSTRASSE 4 MUNICH, 2M 80333	X	X
TVM Life Science Ventures VI LP C/O TVM CAPITAL GROUP OTTOSTRASSE 4 MUNICH, 2M 80333		X

Signatures

/s/ Stefan Fischer, Authorized Officer /s/ Josef Moosholzer, Authorized Officer		02/20/2014
^**Signature of Reporting Person		Date
/s/ Rolf Starck, Attorney-in-Fact for Hubert Birner		02/20/2014
^**Signature of Reporting Person		Date
/s/ Rolf Starck, Attorney-in-Fact for Stefan Fischer		02/20/2014
^**Signature of Reporting Person		Date
/s/ Rolf Starck, Attorney-in-Fact for Alexandra Goll		02/20/2014
^**Signature of Reporting Person		Date
/s/ Rolf Starck, Attorney-in-Fact for Axel Polack		02/20/2014
^**Signature of Reporting Person		Date
/s/ Rolf Starck, Attorney-in-Fact for Helmut Schuhsler		02/20/2014
^**Signature of Reporting Person		Date
/s/ Stefan Fischer, Director /s/ Josef Moosholzer, Officer		02/20/2014
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The Series A, Series B and Series C Convertible Preferred Stock converted into Common Stock on a 1-for-5.65 basis upon the closing of the issuer's initial public offering without payment of consideration.
(2)	The shares are directly held by TVM Life Sciences Ventures VI GMBH & Co. KG ("TVM VI"). Alexandra Goll ("Goll"), Helmut Schuhsler ("Schuhsler"), Hubert Birner ("Birner"), Stefan Fischer ("Fischer") and Alex Polack ("Polack") are members of the investment committee of TVM Life Sciences Ventures VI Management VI Limited Partnership ("TVM VI Management"), a special limited partner of TVM VI, with voting and dispositive power over the shares held by TVM VI. TVM VI Management and these individuals each disclaim beneficial ownership of the shares held by TVM VI except to the extent of any pecuniary interest therein.
(3)	The shares are directly held by TVM Life Sciences Ventures VI LP ("TVM VI LP"). Goll, Schuhsler, Birner, Fischer and Polack are members of the investment committee of TVM VI Management, a special limited partner of TVM VI LP, with voting and dispositive power over the shares held by TVM VI LP. TVM VI Management and these individuals each disclaim beneficial ownership of the shares held by TVM VI LP except to the extent of any pecuniary interest therein.
(4)	Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.